Royal Bank of Canada
PRLD icon

Royal Bank of Canada’s Prelude Therapeutics PRLD Stock Holding History

Royal Bank of Canada’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8K Buy
2,331
+589
+34% +$1.54K ﹤0.01% 6264
2025
Q4 		$5K Sell
1,742
-5,970
-77% -$10.1K ﹤0.01% 6723
2025
Q3 		$11K Buy
7,712
+4,885
+173% +$4.9K ﹤0.01% 6456
2025
Q2 		$2K Sell
2,827
-517
-15% -$448 ﹤0.01% 6814
2025
Q1 		$2K Sell
3,344
-377
-10% -$352 ﹤0.01% 6584
2024
Q4 		$4K Buy
3,721
+866
+30% +$1.15K ﹤0.01% 6594
2024
Q3 		$6K Sell
2,855
-84
-3% -$389 ﹤0.01% 6466
2024
Q2 		$11K Buy
2,939
+886
+43% +$3.61K ﹤0.01% 6307
2024
Q1 		$10K Sell
2,053
-6,987
-77% -$27.2K ﹤0.01% 6212
2023
Q4 		$39K Buy
9,040
+3,977
+79% +$12.1K ﹤0.01% 6099
2023
Q3 		$15K Sell
5,063
-216
-4% -$811 ﹤0.01% 6284
2023
Q2 		$24K Buy
5,279
+21
+0.4% +$125 ﹤0.01% 6123
2023
Q1 		$30K Buy
5,258
+959
+22% +$5.85K ﹤0.01% 5872
2022
Q4 		$26K Buy
4,299
+99
+2% +$634 ﹤0.01% 6196
2022
Q3 		$28K Buy
4,200
+1,699
+68% +$11.5K ﹤0.01% 6012
2022
Q2 		$13K Sell
2,501
-665
-21% -$3.38K ﹤0.01% 6280
2022
Q1 		$22K Sell
3,166
-1,666
-34% -$15.2K ﹤0.01% 6554
2021
Q4 		$61K Sell
4,832
-74
-2% -$1.2K ﹤0.01% 6250
2021
Q3 		$153K Buy
4,906
+1,250
+34% +$40.5K ﹤0.01% 5401
2021
Q2 		$104K Buy
3,656
+207
+6% +$7.37K ﹤0.01% 5581
2021
Q1 		$150K Buy
3,449
+618
+22% +$41K ﹤0.01% 5154
2020
Q4 		$203K Buy
+2,831
New +$141K ﹤0.01% 4846

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada's PRLD Position: Q1 2026 in Review

Royal Bank of Canada increased its Prelude Therapeutics (PRLD) stake by 34% in Q1 2026, buying an estimated $1.54K and bringing the position to 2,331 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #6264.

Royal Bank of Canada first reported a position in PRLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $203K in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Royal Bank of Canada held 2,331 shares of Prelude Therapeutics worth $8K as of Q1 2026.
  • Royal Bank of Canada bought 589 Prelude Therapeutics shares in Q1 2026, an estimated $1.54K.
  • Prelude Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6264 holding.
  • Royal Bank of Canada first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Prelude Therapeutics position peaked at $203K in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.